Healthcare · Pharmaceuticals: Major

Eli Lilly and Company

NYSELLY ISINUS5324571083 SEC CIK0000059478 Listed on NYSE · USD

$1,452.37 +15.08 (+1.05%) Pre-market $1,445.01 (+0.54%) ≈ ₹1.36 L a share

Open chart

Price, last 12 months+55.49% in a year

Key numbers

Market value: $1.37T
P/E (TTM): 47.2
Forward P/E: 35.9
EPS (TTM): $30.81
Dividend yield: 0.48%
Beta: 0.39
Day range: $1,433.17 – $1,460.00
52-week range: $850.51 – $1,460.00
Volume: 612,094
10-day avg volume: $3.75M
Revenue (TTM): $86.46B
EBITDA (TTM): $46.49B
Gross margin: 83.6%
Net margin: 31.9%
Return on equity: 86.1%
Debt / equity: 122.9%
Price / sales: 15.80
Shares out: 940.75M

52W low52W high

Quarterly results

Results for each quarter

Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.

Revenue and net income

$9.35B$2.19B

Dec 23

$8.77B$2.24B

Mar 24

$11.30B$2.97B

Jun 24

$11.44B$970.30M

Sep 24

$13.53B$4.41B

Dec 24

$12.73B$2.76B

Mar 25

$15.56B$5.66B

Jun 25

$17.60B$5.58B

Sep 25

$19.29B$6.64B

Dec 25

$19.80B$7.40B

Mar 26

$22.97B$7.10B

Jun 26

$24.40B$6.45B

Sep 26

Revenue · QoQ (vs last quarter)

—-6.3%+29%+1.2%+18%-5.9%+22%+13%+9.6%+2.6%+16%+6.2%

Revenue · YoY (vs a year ago)

————+45%+45%+38%+54%+43%+56%+48%+39%

Net income · QoQ (vs last quarter)

—+2.4%+32%-67%+354%-37%+105%-1.4%+19%+11%-4.1%-9.1%

Net income · YoY (vs a year ago)

————+101%+23%+91%+475%+51%+168%+25%+16%

RevenueOperating incomeNet incomeLine = trend

US$	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	$9.35B	$8.77B	$11.30B	$11.44B	$13.53B	$12.73B	$15.56B	$17.60B	$19.29B	$19.80B	$22.97B	$24.40B
Cost of revenue	$1.79B	$1.67B	$2.17B	$2.17B	$2.40B	$2.23B	$2.45B	$3.01B	$3.37B	$3.58B	$3.27B	$3.93B
Gross profit	$7.57B	$7.09B	$9.13B	$9.27B	$11.13B	$10.50B	$13.11B	$14.59B	$15.92B	$16.22B	$19.71B	$20.46B
Gross margin	80.9%	80.9%	80.8%	81.0%	82.2%	82.5%	84.3%	82.9%	82.5%	81.9%	85.8%	83.9%
Selling, general & admin	$1.93B	$1.95B	$2.12B	$2.10B	$2.42B	$2.47B	$2.75B	$2.74B	$3.13B	$2.93B	$3.43B	$3.13B
Interest expense	$138.20M	$179.60M	$183.60M	$192.70M	$225.10M	$243.70M	$249.00M	$179.60M	$222.70M	—	—	—
Pre-tax income	$2.51B	$2.54B	$3.52B	$1.59B	$5.04B	$3.46B	$6.78B	$7.23B	$8.27B	$8.85B	$9.25B	$8.41B
Income tax	$318.90M	$293.20M	$550.20M	$618.10M	$628.50M	$697.00M	$1.12B	$1.65B	$1.63B	$1.45B	$2.15B	$1.96B
Net income	$2.19B	$2.24B	$2.97B	$970.30M	$4.41B	$2.76B	$5.66B	$5.58B	$6.64B	$7.40B	$7.10B	$6.45B
Net margin	23.4%	25.6%	26.3%	8.5%	32.6%	21.7%	36.4%	31.7%	34.4%	37.4%	30.9%	26.4%
EPS (diluted)	—	$2.48	$3.28	$1.07	—	$3.06	$6.29	$6.21	—	$8.26	$7.94	$7.22

Income statement

Results for each year

8 fiscal years from the company's 10-K filings with the US SEC.

Revenue, gross profit and net income

$21.49B$16.81B$3.23B

FY18

$22.32B$17.60B$8.32B

FY19

$24.54B$19.06B$6.19B

FY20

$28.32B$21.01B$5.58B

FY21

$28.54B$21.91B$6.24B

FY22

$34.12B$27.04B$5.24B

FY23

$45.04B$36.63B$10.59B

FY24

$65.18B$54.13B$20.64B

FY25

Revenue · YoY (vs a year ago)

—+3.8%+9.9%+15%+0.8%+20%+32%+45%

Net income · YoY (vs a year ago)

—+157%-26%-9.9%+12%-16%+102%+95%

RevenueGross profitNet incomeLine = trend

$3.13

FY18

$8.89

FY19

$6.79

FY20

$6.12

FY21

$6.90

FY22

$5.80

FY23

$11.71

FY24

$22.95

FY25

EPS (diluted) · YoY (vs a year ago)

—+184%-24%-9.9%+13%-16%+102%+96%

EPS (diluted)Line = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$21.49B	$22.32B	$24.54B	$28.32B	$28.54B	$34.12B	$45.04B	$65.18B
Revenue growth	—	3.8%	9.9%	15.4%	0.8%	19.6%	32.0%	44.7%
Cost of revenue	$4.68B	$4.72B	$5.48B	$7.31B	$6.63B	$7.08B	$8.42B	$11.05B
Gross profit	$16.81B	$17.60B	$19.06B	$21.01B	$21.91B	$27.04B	$36.63B	$54.13B
Gross margin	78.2%	78.8%	77.7%	74.2%	76.8%	79.2%	81.3%	83.0%
Research & development	$5.05B	$5.60B	$5.98B	$6.93B	$7.19B	—	—	—
Selling, general & admin	$5.98B	$6.21B	$6.12B	$6.43B	$6.44B	$7.40B	$8.59B	$11.09B
Depreciation & amortisation	$1.61B	$1.23B	$1.32B	$1.55B	$1.52B	$1.53B	$1.77B	$2.00B
Interest expense	$242.50M	$400.60M	$359.60M	$339.80M	$331.60M	$485.90M	$781.00M	$895.00M
Pre-tax income	$3.68B	$5.27B	$7.23B	$6.16B	$6.81B	$6.55B	$12.68B	$25.73B
Income tax	$529.50M	$628.00M	$1.04B	$573.80M	$561.60M	$1.31B	$2.09B	$5.09B
Tax rate	14.4%	11.9%	14.3%	9.3%	8.3%	20.0%	16.5%	19.8%
Net income	$3.23B	$8.32B	$6.19B	$5.58B	$6.24B	$5.24B	$10.59B	$20.64B
Net margin	15.0%	37.3%	25.2%	19.7%	21.9%	15.4%	23.5%	31.7%
EPS (diluted)	$3.13	$8.89	$6.79	$6.12	$6.90	$5.80	$11.71	$22.95

Balance sheet

Assets and debt

At each fiscal year end.

Equity, debt and cash

$9.83B$10.30B$7.41B

FY18

$2.61B$15.32B$2.44B

FY19

$5.64B$16.60B$3.68B

FY20

$8.98B$16.88B$3.91B

FY21

$10.65B$16.24B$2.21B

FY22

$10.77B$25.23B$2.93B

FY23

$14.27B$33.64B$3.42B

FY24

$26.54B$42.50B$7.27B

FY25

Shareholders' equity · YoY (vs a year ago)

—-73%+116%+59%+19%+1.1%+32%+86%

Shareholders' equityTotal debtCash + short-term investmentsLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & equivalents	$7.32B	$2.34B	$3.66B	$3.82B	$2.07B	$2.82B	$3.27B	$7.27B
Short-term investments	$88.20M	$101.00M	$24.20M	$90.10M	$144.80M	$109.10M	$154.80M	—
Current assets	$20.55B	$13.71B	$17.46B	$18.45B	$18.03B	$25.73B	$32.74B	$55.63B
Total assets	$43.91B	$39.29B	$46.63B	$48.81B	$49.49B	$64.01B	$78.72B	$112.48B
Current liabilities	$11.89B	$11.78B	$12.48B	$15.05B	$17.14B	$27.29B	$28.38B	$35.23B
Long-term debt	$9.20B	$13.82B	$16.59B	$15.35B	$14.74B	$18.32B	$28.53B	$40.87B
Short-term debt	$1.10B	$1.50B	$8.70M	$1.54B	$1.50B	$6.90B	$5.12B	$1.64B
Total debt	$10.30B	$15.32B	$16.60B	$16.88B	$16.24B	$25.23B	$33.64B	$42.50B
Shareholders' equity	$9.83B	$2.61B	$5.64B	$8.98B	$10.65B	$10.77B	$14.27B	$26.54B
Current ratio	1.73	1.16	1.40	1.23	1.05	0.94	1.15	1.58
Debt / equity	1.05	5.88	2.94	1.88	1.52	2.34	2.36	1.60
Return on equity	32.9%	319.1%	109.8%	62.2%	58.6%	48.6%	74.2%	77.8%

Cash flow

Cash coming in and going out

Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.

Free cash flow and shareholder returns

$5.52B$5.52B$6.46B

FY18

$4.84B$4.84B$6.81B

FY19

$6.50B$6.50B$3.19B

FY20

$7.37B$7.37B$4.34B

FY21

$7.59B$7.59B$5.04B

FY22

$4.24B$4.24B$4.82B

FY23

$8.82B$8.82B$7.18B

FY24

$16.81B$16.81B$9.49B

FY25

Operating cash flow · YoY (vs a year ago)

—-12%+34%+13%+3.0%-44%+108%+91%

Free cash flow · YoY (vs a year ago)

—-12%+34%+13%+3.0%-44%+108%+91%

Operating cash flowFree cash flowDividends + buybacksLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash from operations	$5.52B	$4.84B	$6.50B	$7.37B	$7.59B	$4.24B	$8.82B	$16.81B
Free cash flow	$5.52B	$4.84B	$6.50B	$7.37B	$7.59B	$4.24B	$8.82B	$16.81B
FCF margin	25.7%	21.7%	26.5%	26.0%	26.6%	12.4%	19.6%	25.8%
Stock-based pay	$279.50M	$312.40M	$308.10M	$342.80M	$371.10M	$629.00M	$646.00M	$626.00M
Cash from investing	$1.91B	$-8.08B	$-2.26B	$-2.87B	$-3.76B	$-7.15B	$-9.30B	$-10.97B
Cash from financing	$-5.90B	$-2.32B	$-3.14B	$-4.13B	$-5.41B	$3.50B	$1.23B	$-2.21B
Dividends paid	$-2.31B	$-2.41B	$-2.69B	$-3.09B	$-3.54B	$-4.07B	$-4.68B	$-5.38B
Share buybacks	$-4.15B	$-4.40B	$-500.00M	$-1.25B	$-1.50B	$-750.00M	$-2.50B	$-4.11B

About

About Eli Lilly and Company

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Eli Lilly and Company
Ticker: LLY
Exchange: NYSE
ISIN: US5324571083
SEC CIK: 0000059478
Sector: Healthcare
Industry: Pharmaceuticals: Major
SEC industry (SIC): Pharmaceutical Preparations (2834)
Incorporated in: Indiana
Financial year ends: 31 December
Filer type: Large accelerated filer
Latest annual report (10-K): 12 Feb 2026
CEO: David A. Ricks
Chair: David A. Ricks
Headquarters: Indianapolis
Address: Lilly Corporate Ctr, Drop Code 1094, Indianapolis, In 46285
Founded: 1876
Employees: 50,000
Formerly known as: Lilly Eli & Co, Lilly Eli & Co Et Al
Trades in: US dollars (USD)
Website: lilly.com

News

Peers

Others in Healthcare

Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Eli Lilly and Company

Key numbers

Quarterly results

Revenue and net income

Income statement

Revenue, gross profit and net income

Balance sheet

Equity, debt and cash

Cash flow

Free cash flow and shareholder returns

About

Company details

News

Peers